Atorvastatin

Evidence Level: L5

Predicted Indications: 6

Atorvastatin
Atorvastatin: From Hyperlipidemia (label text not supplied) to Familial Hypercholesterolemia

## Pharmacist Assessment Report

Atorvastatin: From Hyperlipidemia (label text not supplied) to Familial Hypercholesterolemia

One-Sentence Summary

Atorvastatin is a statin (HMG-CoA reductase inhibitor) marketed in the US as many generic products. The supplied license data do not include the approved indication text. The TxGNN model predicts it may be effective for familial hypercholesterolemia (FH), with 35 clinical trials (most of them combination or background-therapy studies) and 19 publications currently supporting this direction. This is probably an already-established use rather than true repurposing, so the label status should be verified.

Quick Overview

Item	Content
Original Indication	Not available (all approved-indication fields in the license data are empty)
Predicted New Indication	Familial hypercholesterolemia
TxGNN Prediction Score	99.42%
Evidence Level	L1 (see caveat under Clinical Trial Evidence)
US Market Status	✓ Marketed
Number of NDAs	20 (all five listed licenses are ANDA generics)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

The supplied mechanism-of-action field is empty. Based on the pack’s mechanistic analysis, atorvastatin inhibits HMG-CoA reductase, which upregulates hepatic LDL receptors and lowers LDL cholesterol. This is a direct, established mechanism for FH caused by LDL-receptor dysfunction.

The relationship between the original and new indication is close. Both are disorders of elevated LDL cholesterol, and FH is the genetic form of the same problem statins are designed to treat. Because the original-indication field is empty, this is probably an already-labeled use rather than a true repurposing case.

There is one mechanistic limit. Response in homozygous FH is limited because statins depend on residual LDL-receptor function. This is why trials in that population add ezetimibe, PCSK9 inhibitors, or other agents on top of atorvastatin.

Clinical Trial Evidence

Atorvastatin is usually background therapy or a comparator in these trials, so they mainly show the combination or the population rather than atorvastatin alone. The ten most relevant are listed below.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00827606	Phase 3	Completed	272	3-year open-label study of atorvastatin in children and adolescents with heterozygous FH, tracking growth, development and cholesterol reduction
NCT00739999	Phase 1	Completed	39	8-week open-label PK/PD and safety study of atorvastatin in pediatric heterozygous FH (supports dosing and safety, not efficacy)
NCT00134485	Phase 3	Completed	400	Torcetrapib/atorvastatin vs maximally tolerated atorvastatin alone in heterozygous FH; the torcetrapib program was terminated for safety findings
NCT00136981	Phase 3	Completed	800	24-month carotid ultrasound trial of torcetrapib/atorvastatin vs atorvastatin alone in heterozygous FH
NCT03884452	Phase 3	Completed	50	Ezetimibe added to atorvastatin or simvastatin in homozygous FH
NCT03885921	Phase 3	Completed	44	Up to 24 months of long-term safety follow-up of ezetimibe plus atorvastatin or simvastatin in homozygous FH
NCT03867318	Phase 3	Completed	621	Double-blind trial of ezetimibe added to atorvastatin 10 mg in heterozygous FH, CHD, or multiple risk factors
NCT03882996	Phase 3	Completed	432	Up to 12 months of long-term safety of ezetimibe plus atorvastatin 10–80 mg
NCT01730040	Phase 3	Completed	355	Alirocumab added to atorvastatin vs ezetimibe added vs atorvastatin dose increase vs switch to rosuvastatin
NCT02460159	Phase 3	Completed	135	Long-term safety of ezetimibe/atorvastatin fixed-dose combination in Japanese patients with hypercholesterolemia

Evidence-level caveat: L1 is met by the number of completed Phase 3 trials, but most are randomized combination or add-on designs. The only atorvastatin-focused Phase 3 study in the list, NCT00827606, is open-label and single-arm. Direct atorvastatin-alone efficacy evidence in FH therefore comes mostly from the literature below.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27678432	2016	Clinical study (not classified)	J Clin Lipidol	3-year study of atorvastatin in children and adolescents (from age 6) with heterozygous FH; extends prior trials of up to 1 year on efficacy and safety
11383320	2001	Comparative study (not classified)	Nutr Metab Cardiovasc Dis	Atorvastatin vs simvastatin for reaching the NCEP LDL-C goal in heterozygous FH, with effects on fibrinogen and coagulation variables
27417002	2016	Study (not classified)	J Am Coll Cardiol	Quantifies statin-related reduction in coronary artery disease events and mortality in heterozygous FH
22957727	2013	Clinical study (not classified)	Echocardiography	Atorvastatin effects on myocardial and peripheral blood flow in FH patients without coronary atherosclerosis
39751968	2025	Review	Curr Atheroscler Rep	Review of novel LDL-C-lowering therapies in homozygous FH
9793596	1998	Review	Ann Pharmacother	Review of atorvastatin efficacy and safety in primary hypercholesterolemia and mixed dyslipidemias
28437620	2017	Guideline	Endocr Pract	AACE/ACE guidelines for dyslipidemia management and cardiovascular prevention
30270066	2018	Retrospective study	Atherosclerosis	Real-world FH treatment in Slovakia; maximal-dose potent statins are the cornerstone, yet many patients miss LDL-C goals
35361995	2022	Genetic study	Pharmacogenomics J	Combines FH gene panel with statin pharmacogenomics for genotype-guided prescribing
40254247	2025	Preclinical	Toxicology	Lipophilic vs hydrophilic statin myotoxicity in iPSC-derived muscle cells from FH patients with statin-associated muscle symptoms

US Market Information

The license data show 20 licenses in total; five are listed. All are ANDA generics, and none includes approved-indication text.

Authorization Number	Product Name	Dosage Form	Approved Indication
ANDA091226	Atorvastatin Calcium (Mylan Pharmaceuticals Inc.)	Tablet, film coated	Not provided
ANDA206536	atorvastatin calcium (Zydus Pharmaceuticals USA Inc.)	Tablet	Not provided
ANDA205300	Atorvastatin Calcium (Teva Pharmaceuticals USA, Inc.)	Tablet, film coated	Not provided
ANDA206536	atorvastatin calcium (Zydus Lifesciences Limited)	Tablet	Not provided
ANDA204991	Atorvastatin Calcium (Bryant Ranch Prepack)	Tablet	Not provided

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Atorvastatin has a direct, well-established mechanism for lowering LDL-C in FH, and many completed Phase 3 trials and clinical studies involve it in FH populations. Most trials test add-on or combination regimens, however, and the missing label and safety data mean this should not be treated as a clean repurposing finding yet.

To proceed, the following is needed:

Verify the current US label to confirm whether FH is already an approved indication. If it is, this is not a repurposing candidate.
Obtain the package insert warnings and contraindications (blocking data gap DG001), and complete the safety screen.
Obtain the mechanism-of-action record (DG002), for example from the DrugBank API.
Separate atorvastatin-alone efficacy from combination-therapy evidence, especially for homozygous FH, where the effect depends on residual LDL-receptor function.
Consider a pediatric-specific safety review, since much of the atorvastatin-focused evidence is in children and adolescents.

This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.